Pfizer Inc. (PFE) Revenue by Segment
Pfizer revenue by segment at a glance
In Q1 fiscal 2024 (the quarter ended March 31, 2024), Pfizer's largest business segment was Biopharma, with $14.60 billion or 98% of revenue, down 19.6% from a year earlier. Next: Business Innovation (2%).
By product or service, Eliquis brought in 17%, Vyndaqel brought in 12% and Prevnar Prevenar Family brought in 9% of revenue in Q2 fiscal 2026.
By region, United States brought in 59%, International Developed Markets brought in 25% and International Emerging Markets brought in 16% of revenue in Q2 fiscal 2026.
From company filings, in USD; latest quarter ended March 31, 2024; quarterly data from Q3 fiscal 2017.
Pfizer Inc.
Revenue breakdown
Fiscal quarters, from company filings
Pfizer revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Biopharma | $14.7B | $14.2B | $16.3B | $14.3B | 98% |
| Business Innovation | – | – | – | – | 2% |
In USD, fiscal quarters as reported; share = part of Q1 FY24 revenue.
Pfizer revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Eliquis | $2.4B | $2.2B | $2.0B | $2.0B | 17% |
| Vyndaqel | $1.8B | $1.6B | $1.6B | $1.6B | 12% |
| Prevnar Prevenar Family | $1.3B | $1.7B | $1.7B | $1.4B | 9% |
| Ibrance | $1.1B | $1.0B | $1.1B | $1.0B | 7% |
| All Other Hospital and Biosimilars | $952.0M | $953.0M | – | $934.0M | 6% |
| Other Primary Care Products | $699.0M | $654.0M | $721.0M | $731.0M | 5% |
| Padcev | $667.0M | $591.0M | $464.0M | $542.0M | 5% |
| Other Specialty Care | $566.0M | $579.0M | $407.0M | $453.0M | 4% |
| Xtandi | $534.0M | $444.0M | $578.0M | $566.0M | 4% |
| Nurtec ODT/Vydura | $421.0M | $353.0M | $412.0M | $359.0M | 3% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Pfizer revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $8.9B | $8.7B | $10.7B | $8.9B | 59% |
| International Developed Markets | $3.7B | $3.4B | $3.7B | $3.4B | 25% |
| International Emerging Markets | $2.4B | $2.3B | $2.3B | $2.4B | 16% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
What are Pfizer's business segments?
Biopharma and Business Innovation (as reported for Q1 fiscal 2024).
Which business segment makes the most money for Pfizer?
Biopharma: $14.60 billion, or 98% of revenue, in Q1 fiscal 2024.
What are Pfizer's main products and services?
By revenue in Q2 fiscal 2026: Eliquis (17%), Vyndaqel (12%), Prevnar Prevenar Family (9%) and Ibrance (7%).
Where does Pfizer make its money?
By region in Q2 fiscal 2026: United States (59%), International Developed Markets (25%) and International Emerging Markets (16%).
